

Kidney Transplant Recipients

Post Kidney Transplantation, Genotype 1–6

Recommended and alternative regimens listed by pangenotypic, evidence level, and alphabetically for:

Treatment-Naive Kidney Transplant Recipients Without Direct-Acting Antiviral Experience With Genotype 1–6 Infection, With or Without Compensated Cirrhosis^a **i**

RECOMMENDED	DURATION	RATING i
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b	12 weeks	I, A ^c IIa, C ^d
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	IIa, C
Genotype 1, 4, 5, or 6 only: Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
ALTERNATIVE	DURATION	RATING i
Genotype 1 or 4 only: Daily fixed-dose combination of elbasvir (50 mg)/ grazoprevir (100 mg) for persons without baseline NS5A resistance-associated substitution(s) ^e for elbasvir	12 weeks	I, B

^a For [decompensated cirrhosis](#), please refer to the appropriate section.

^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

^c Based on evidence for persons without cirrhosis.

^d Based on evidence for persons with compensated cirrhosis.

^e Includes genotype 1a resistance-associated substitutions at amino acid positions 28, 30, 31, or 93 known to confer [antiviral resistance](#).

Recommended regimen for:

Kidney Transplant Recipients With Direct-Acting Antiviral Experience and Genotype 1–6 Infection, With or Without Compensated Cirrhosis^a

RECOMMENDED	DURATION	RATING i
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg), with or	12 weeks	IIa, C

Recommended regimen for:

Kidney Transplant Recipients With Direct-Acting Antiviral Experience and Genotype 1–6 Infection, With or Without Compensated Cirrhosis^a

without ribavirin^b

^a Excludes persons with CTP class B and class C cirrhosis. For [decompensated cirrhosis](#), please refer to the appropriate section.

^b For persons with cirrhosis and multiple negative baseline characteristic, consideration should be given to adding ribavirin. If renal dysfunction is present, a lower starting dosage of ribavirin is recommended. Maximum ribavirin dosage is 1000 mg/d for persons who weigh <75 kg and 1200 mg/d for those who weigh ≥75 kg.

For additional information on treatment of DAA failures post transplant, treatment of decompensated cirrhosis following transplantation, treatment of transplant recipients from HCV-positive donors, and post transplant drug-drug interactions, please see [Persons Who Develop Recurrent HCV Infection Post Liver Transplantation](#).

Recommended Regimens

Glecaprevir/Pibrentasvir

The phase 3, open-label, single arm MAGELLAN-2 study evaluated a 12-week course of the pangenotypic regimen of glecaprevir (300 mg)/pibrentasvir (120 mg) in 100 liver (n=80) and kidney (n=20) transplant recipients with genotypes 1 through 6 infection who were at least 3 months post transplant. People with cirrhosis were excluded. SVR12 was achieved in 98% of participants; a single recipient experienced virologic failure ([Reau 2018](#)). The safety profile was excellent with 1 treatment discontinuation for an adverse event not considered to be therapy related. One rejection episode occurred in a liver transplant recipient. While glecaprevir/pibrentasvir is an effective pangenotypic regimen as demonstrated in the nontransplant population, there were no genotype 5 transplant recipients in the study.

There are potential drug-drug interactions with cyclosporine. Review the [DAA interactions with calcineurin inhibitors](#) table in the post liver transplantation section before prescribing HCV direct-acting antiviral (DAA) therapy to a renal transplant recipient.

Ledipasvir/Sofosbuvir

A phase 2, open-label clinical trial evaluated the safety and efficacy of the daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) among 114 kidney transplant recipients who were more than 6 months post transplant ([Colombo, 2017](#)). Enrollees had genotype 1 (91%) or 4 infection; 69% were treatment naive and 15% had compensated cirrhosis. Participants were randomized to 12 weeks or 24 weeks of ledipasvir/sofosbuvir. Median estimated glomerular filtration rate (eGFR) prior to treatment was 50 mL/min/1.73 m² for participants in the 12-week study arm and 60 mL/min/1.73 m² for those in the 24-week arm. The overall SVR12 rate was 100% (114/114). Adverse events were common (64%) and serious adverse events occurred in 13 participants; a single participant discontinued treatment because of an adverse event. Four participants with an eGFR >40 mL/min/1.73 m² at baseline experienced a decrease to <30 mL/min/1.73 m² during therapy.

The eGFR increased to >30 mL/min/1.73 m² at the last visit recorded in 3 of these participants. One person who had interrupted study treatment had a final eGFR of 14.4 mL/min/1.73 m². All but 1 of the 6 participants with compensated cirrhosis whose eGFR decreased to <40 mL/min/1.73 m² continued study treatment without interruption; none permanently discontinued study treatment.

Several additional reports have described successful outcomes with combination DAA therapy in kidney transplant recipients ([Saxena, 2017](#)); ([Sawinski, 2016](#)). One study evaluated treatment safety and efficacy among 20 kidney transplant recipients with HCV infection (88% genotype 1; 50% advanced fibrosis; 60% treatment experienced with an interferon-based regimen) who received sofosbuvir-based therapy. Various regimens were used, including simeprevir plus sofosbuvir (n=9); ledipasvir/sofosbuvir (n=7); sofosbuvir plus ribavirin (n=3); and daclatasvir plus sofosbuvir (n=1). SVR12 rate was 100% ([Sawinski, 2016](#)). Two participants required dosage reductions due to anemia associated with ribavirin use. However, no significant changes in serum creatinine or proteinuria, or graft rejection were seen before or after treatment. Forty-five percent of participants required a dosage reduction of immunosuppressive agents while on DAA therapy.

Real-world data from the ongoing HCV-TARGET study have also demonstrated the efficacy of DAA therapy in persons with a kidney transplant and in those with dual liver and kidney transplant ([Saxena, 2017](#)). Various regimens were used, including sofosbuvir/ledipasvir ± ribavirin (85%); sofosbuvir plus daclatasvir ± ribavirin (9%); and ombitasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin (6%). SVR12 rate was 95% in those with a kidney transplant and 91% in dual liver and kidney transplant recipients.

No change in calcineurin inhibitor dosage is needed for people receiving ledipasvir/sofosbuvir. Review the [DAA interactions with calcineurin inhibitors](#) table in the post liver transplantation section before prescribing HCV DAA therapy to a renal transplant recipient.

Sofosbuvir/Velpatasvir

There are no published clinical trials regarding the use of the fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) in kidney transplant recipients. There are, however, significant data addressing the efficacy and safety of this regimen in the nontransplant and liver transplant settings.

In liver transplant recipients (discussed in [Persons Who Develop Recurrent HCV Infection Post Liver Transplantation](#)), the safety and efficacy of sofosbuvir/velpatasvir for 12 weeks was evaluated in 79 adults (n=5 cirrhosis; n=4 DAA experienced) with genotype 1, 2, 3, or 4 infection ([Agarwal, 2018](#)). Treatment was well-tolerated with 99% of participants completing treatment. SVR12 rates by genotype were 93% genotype 1a (n=15); 96% genotype 1b (n=22); 100% genotype 2 (n=3); 97% genotype 3 (n=35); and 100% genotype 4 (n=4).

In the nontransplant setting (discussed in detail in the [Initial](#) and [Retreatment](#) sections), the phase 3, double-blind, placebo-controlled ASTRAL-1 study demonstrated an overall SVR rate of 99% among 742 treatment-naive or treatment-experienced adults with genotype 1, 2, 4, 5, or 6 infection ([Feld, 2015](#)). In the phase 3, open-label ASTRAL-3 study, 552 treatment-naive or treatment-experienced adults with genotype 3 infection (with or without compensated cirrhosis) were randomized in a 1:1 ratio to 12 weeks of sofosbuvir/velpatasvir or 24 weeks of sofosbuvir plus weight-based ribavirin. SVR12 rate was 95% for the sofosbuvir/velpatasvir treatment arm, which was superior to the SVR12 rate of 80% among participants receiving sofosbuvir plus ribavirin for 24 weeks ([Foster, 2015a](#)).

No change in calcineurin inhibitor dosage is needed for persons receiving sofosbuvir/velpatasvir. Review the [DAA interactions with calcineurin inhibitors](#) table in the post liver transplantation section before prescribing HCV DAA therapy to a renal transplant recipient.

Sofosbuvir/Velpatasvir/Voxilaprevir

To date, there are no published clinical trials evaluating use of the daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) in kidney transplant recipients. There are, however, significant data addressing the efficacy and safety of this regimen in the nontransplant setting ([Degasperi, 2019](#)); ([Llaneras, 2019](#)); (Bourlière, 2017); ([Jacobson, 2017](#)); ([Soriano, 2017](#)); ([Saxena, 2016](#)).

Two phase 3, open label, randomized clinical trials were conducted to determine the safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in adults (nontransplant recipients) previously treated with a DAA regimen. The POLARIS-1 study included adults (nontransplant recipients) who had previously received a regimen containing an NS5A inhibitor. Participants were randomized to 12 weeks of sofosbuvir/velpatasvir/voxilaprevir or placebo. SVR rate for participants on active treatment was 96% (Bourlière, 2017). POLARIS-4 compared 12 weeks of sofosbuvir/velpatasvir/voxilaprevir to 12 weeks of sofosbuvir/velpatasvir in non-NS5A inhibitor DAA-experienced adults (nontransplant recipients) (Bourlière, 2017). Overall, 69% of participants were previously exposed to sofosbuvir plus ribavirin ± peginterferon, and 11% were exposed to sofosbuvir plus simeprevir. Cirrhosis was common, 46% in both study arms. SVR12 rates were 98% with sofosbuvir/velpatasvir/voxilaprevir and 90% with sofosbuvir/velpatasvir.

Velpatasvir is a substrate for cytochrome P450 (CYP) 3A4, 2C8, and 2B6, a weak inhibitor of P-glycoprotein (P-gp) and organic anion-transporting polypeptides (OATP), and a moderate inhibitor of the breast cancer resistance protein (BCRP) membrane transporter. As such, velpatasvir is moderately affected by potent inhibitors and, to a greater extent, potent inducers of enzyme/drug transporter systems ([Mogalian, 2016](#)). Based on this profile, which is similar to ledipasvir, clinically significant drug-drug interactions would not be expected for coadministration of sofosbuvir/velpatasvir with common immunosuppressive agents (eg, tacrolimus, cyclosporine, corticosteroids, mycophenolate mofetil, or everolimus). Review the [DAA interactions with calcineurin inhibitors](#) table in the post liver transplantation section before prescribing HCV DAA therapy to a renal transplant recipient.

Alternative Regimen

Elbasvir/Grazoprevir

Data from small, real-world studies evaluating elbasvir/grazoprevir are available. One such study evaluated 11 kidney transplant recipients with significant kidney function impairment (GFR <40 mL/min/1.73 m²) treated with elbasvir/grazoprevir for 12 weeks to 16 weeks. SVR12 rate was 100% ([Eisenberger, 2018](#)).

There are significant drug-drug interactions with cyclosporine. Review the [DAA interactions with calcineurin inhibitors](#) table in the post liver transplantation section before prescribing HCV DAA therapy to a renal transplant recipient.

Related References

Agarwal K, Castells L, Mullhaupt B, et al. [Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients](#). *J Hepatol*. 2018;69(3):603-607. doi:10.1016/j.jhep.2018.05.039.

Bourlière M, Gordon SC, Flamm SL, et al. [Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection](#). *N Engl J Med*. 2017;376(22):2134-2146.

- Colombo M, Aghemo A, Liu H, et al. [Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial.](#) *Ann Intern Med.* 2017;166(2):109-117.
- Degasperi E, Spinetti A, Lombardi A, et al. [Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.](#) *J Hepatol.* 2019;71(6):1106-1115. doi:10.1016/j.jhep.2019.07.020.
- Durand CM, Bowring MG, Brown DM, et al. [Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial.](#) *Ann Intern Med.* 2018;168(8):533-540.
- Eisenberger U, Friebus-Kardash J, Guberina H, et al. [Treatment with grazoprevir/elbasvir for renal transplant recipients with chronic hepatitis C virus infection and impaired allograft function.](#) *Transplant Direct.* 2018;5(1):e419. doi: 10.1097/TXD.0000000000000860.
- Feld JJ, Jacobson IM, Hézode C, et al. [Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.](#) *N Engl J Med.* 2015;373(27):2599-2607.
- Foster GR, Afdhal NH, Roberts SK. [Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.](#) *N Engl J Med.* 2015;373(27):2608-2617.
- Goldberg DS, Abt P, Reese PP, et al. [Transplanting HCV-infected kidneys into uninfected recipients.](#) *N Engl J Med.* 2017;377(11):1105. doi:10.1056/NEJMc1709315.
- Jacobson IM, Lawitz E, Gane EJ, et al. [Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials.](#) *Gastroenterology.* 2017;153(1):113-122.
- Llaneras J, Riveiro-Barciela M, Lens S, et al. [Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.](#) *J Hepatol.* 2019;71(4):666-672.
- Mogalian E, German P, Kearney BP, et al. [Use of multiple probes to assess transporter- and cytochrome P450-mediated drug-drug interaction potential of the pangenotypic HCV NS5A inhibitor velpatasvir.](#) *Clin Pharmacokinet.* 2016;55(5):605-613. doi: 10.1007/s40262-015-0334-7.
- Reau N, Kwo PY, Rhee S, et al. [Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection.](#) *Hepatology.* 2018;68(4):1298-1307.
- Reese PP, Abt PL, Blumberg EA, et al. [Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial.](#) *Ann Intern Med.* 2018;169(5):273-281. doi:10.7326/M18-0749.
- Sawinski D, Kaur N, Ajeti A, et al. [Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents.](#) *Am J Transplant.* 2016;16(5):1588-1595.
- Saxena V, Korashy FM, Sise ME, et al; HCV-Target. [Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.](#) *Liver Int.* 2016;36(6):807-816.
- Saxena V, Khungar V, Verna EC, et al. [Safety and efficacy of current DAA regimens in kidney and liver transplant recipients with hepatitis C: results from the HCV-TARGET study.](#) *Hepatology.* 2017;66(4):1090-1101.
- Soriano V, Benítez-Gutiérrez L, Arias A, et al. [Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.](#) *Expert Opin Drug Metab Toxicol.* 2017;13(9):1015-1022.

Last Update: October 24, 2022

Last Review: January 15, 2025